Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma Co N.V (NAMS) Liabilities and Shareholders Equity: 2022-2024

Historic Liabilities and Shareholders Equity for NewAmsterdam Pharma Co N.V (NAMS) over the last 3 years, with Dec 2024 value amounting to $864.6 million.

  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity rose 79.06% to $786.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year increase of 90.80%. This contributed to the annual value of $864.6 million for FY2024, which is 149.10% up from last year.
  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity amounted to $864.6 million in FY2024, which was up 149.10% from $347.1 million recorded in FY2023.
  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity's 5-year high stood at $864.6 million during FY2024, with a 5-year trough of $531,583 in FY2022.
  • Its 3-year average for Liabilities and Shareholders Equity is $404.1 million, with a median of $347.1 million in 2023.
  • Data for NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity shows a peak YoY surged of 65,194.98% (in 2023) over the last 5 years.
  • NewAmsterdam Pharma Co N.V's Liabilities and Shareholders Equity (Yearly) stood at $531,583 in 2022, then skyrocketed by 65,194.98% to $347.1 million in 2023, then soared by 149.10% to $864.6 million in 2024.